Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
1
PTPI Quote, Financials, Valuation and Earnings
Last price:
$0.0100
Seasonality move
:
20.28%
Day range:
$0.0091 - $0.0111
52-week range:
$0.0075 - $16.2500
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.22x
P/B ratio:
0.15x
Volume:
97.8K
Avg. volume:
212K
1-year change:
-99.88%
Market cap:
$492.4K
Revenue:
$5.1M
EPS (TTM):
-$36.58
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PTPI
Petros Pharmaceuticals, Inc.
|
$1.3M | -$0.29 | -19.98% | -89.83% | -- |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$3M | -$0.88 | 14.03% | -95.43% | $0.85 |
|
NNVC
NanoViricides, Inc.
|
-- | -$0.08 | -- | -42.49% | $6.50 |
|
OGEN
Oragenics, Inc.
|
-- | -- | -- | -- | $2.00 |
|
PTN
Palatin Technologies
|
-- | -$0.17 | -- | -67.93% | -- |
|
TOVX
Theriva Biologics, Inc.
|
-- | -$0.38 | -- | -94.42% | $7.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PTPI
Petros Pharmaceuticals, Inc.
|
$0.0092 | -- | $492.4K | -- | $0.00 | 0% | 0.22x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$5.43 | $0.85 | $684.2M | 9.12x | $0.80 | 0% | 10.55x |
|
NNVC
NanoViricides, Inc.
|
$1.25 | $6.50 | $22.5M | -- | $0.00 | 0% | -- |
|
OGEN
Oragenics, Inc.
|
$0.83 | $2.00 | $685.6K | -- | $0.00 | 0% | 0.53x |
|
PTN
Palatin Technologies
|
$0.09 | -- | $2.4M | -- | $0.00 | 0% | -- |
|
TOVX
Theriva Biologics, Inc.
|
$0.19 | $7.00 | $6.5M | -- | $0.00 | 0% | 0.33x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PTPI
Petros Pharmaceuticals, Inc.
|
-- | -1.669 | -- | 2.20x |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
37.25% | 2.113 | 8.08% | 1.85x |
|
NNVC
NanoViricides, Inc.
|
-- | 0.464 | -- | 0.95x |
|
OGEN
Oragenics, Inc.
|
3.86% | -0.075 | 36.62% | 3.97x |
|
PTN
Palatin Technologies
|
-- | 1.358 | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
29.07% | -3.365 | 66.16% | 0.68x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PTPI
Petros Pharmaceuticals, Inc.
|
-- | -$990.7K | -789% | -55.57% | -130.8% | -$1.1M |
|
NBY
NovaBay Pharmaceuticals, Inc.
|
$42K | -$1.2M | -208.55% | -306.03% | -224.38% | -$1.8M |
|
NNVC
NanoViricides, Inc.
|
-$132.8K | -$1.8M | -92.29% | -92.29% | -- | -$1.7M |
|
OGEN
Oragenics, Inc.
|
-- | -$3.1M | -311.49% | -509.23% | -- | -$3M |
|
PTN
Palatin Technologies
|
-- | -- | -- | -- | -- | -- |
|
TOVX
Theriva Biologics, Inc.
|
-$28K | -$4.4M | -148.18% | -171.04% | -- | -$4.3M |
Petros Pharmaceuticals, Inc. vs. Competitors
-
Which has Higher Returns PTPI or NBY?
NovaBay Pharmaceuticals, Inc. has a net margin of -140.87% compared to Petros Pharmaceuticals, Inc.'s net margin of -255.85%. Petros Pharmaceuticals, Inc.'s return on equity of -55.57% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.
Company Gross Margin Earnings Per Share Invested Capital PTPIPetros Pharmaceuticals, Inc.81.79% -$0.03 $3.4M NBYNovaBay Pharmaceuticals, Inc.8.06% -$0.22 $2.6M -
What do Analysts Say About PTPI or NBY?
Petros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 271639.13%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -84.35%. Given that Petros Pharmaceuticals, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Petros Pharmaceuticals, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTPIPetros Pharmaceuticals, Inc.0 0 0 NBYNovaBay Pharmaceuticals, Inc.1 0 0 -
Is PTPI or NBY More Risky?
Petros Pharmaceuticals, Inc. has a beta of 2.445, which suggesting that the stock is 144.544% more volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.
-
Which is a Better Dividend Stock PTPI or NBY?
Petros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Petros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTPI or NBY?
Petros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Petros Pharmaceuticals, Inc.'s net income of -$922.7K is higher than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Petros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 9.12x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Petros Pharmaceuticals, Inc. is 0.22x versus 10.55x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTPIPetros Pharmaceuticals, Inc.0.22x -- -- -$922.7K NBYNovaBay Pharmaceuticals, Inc.10.55x 9.12x $521K -$1.3M
-
Which has Higher Returns PTPI or NNVC?
NanoViricides, Inc. has a net margin of -140.87% compared to Petros Pharmaceuticals, Inc.'s net margin of --. Petros Pharmaceuticals, Inc.'s return on equity of -55.57% beat NanoViricides, Inc.'s return on equity of -92.29%.
Company Gross Margin Earnings Per Share Invested Capital PTPIPetros Pharmaceuticals, Inc.81.79% -$0.03 $3.4M NNVCNanoViricides, Inc.-- -$0.10 $7.2M -
What do Analysts Say About PTPI or NNVC?
Petros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 271639.13%. On the other hand NanoViricides, Inc. has an analysts' consensus of $6.50 which suggests that it could grow by 420%. Given that Petros Pharmaceuticals, Inc. has higher upside potential than NanoViricides, Inc., analysts believe Petros Pharmaceuticals, Inc. is more attractive than NanoViricides, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTPIPetros Pharmaceuticals, Inc.0 0 0 NNVCNanoViricides, Inc.1 0 0 -
Is PTPI or NNVC More Risky?
Petros Pharmaceuticals, Inc. has a beta of 2.445, which suggesting that the stock is 144.544% more volatile than S&P 500. In comparison NanoViricides, Inc. has a beta of 1.158, suggesting its more volatile than the S&P 500 by 15.816%.
-
Which is a Better Dividend Stock PTPI or NNVC?
Petros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NanoViricides, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Petros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. NanoViricides, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTPI or NNVC?
Petros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than NanoViricides, Inc. quarterly revenues of --. Petros Pharmaceuticals, Inc.'s net income of -$922.7K is higher than NanoViricides, Inc.'s net income of -$1.8M. Notably, Petros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while NanoViricides, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Petros Pharmaceuticals, Inc. is 0.22x versus -- for NanoViricides, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTPIPetros Pharmaceuticals, Inc.0.22x -- -- -$922.7K NNVCNanoViricides, Inc.-- -- -- -$1.8M
-
Which has Higher Returns PTPI or OGEN?
Oragenics, Inc. has a net margin of -140.87% compared to Petros Pharmaceuticals, Inc.'s net margin of --. Petros Pharmaceuticals, Inc.'s return on equity of -55.57% beat Oragenics, Inc.'s return on equity of -509.23%.
Company Gross Margin Earnings Per Share Invested Capital PTPIPetros Pharmaceuticals, Inc.81.79% -$0.03 $3.4M OGENOragenics, Inc.-- -$1.96 $10.2M -
What do Analysts Say About PTPI or OGEN?
Petros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 271639.13%. On the other hand Oragenics, Inc. has an analysts' consensus of $2.00 which suggests that it could grow by 140.07%. Given that Petros Pharmaceuticals, Inc. has higher upside potential than Oragenics, Inc., analysts believe Petros Pharmaceuticals, Inc. is more attractive than Oragenics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTPIPetros Pharmaceuticals, Inc.0 0 0 OGENOragenics, Inc.1 0 0 -
Is PTPI or OGEN More Risky?
Petros Pharmaceuticals, Inc. has a beta of 2.445, which suggesting that the stock is 144.544% more volatile than S&P 500. In comparison Oragenics, Inc. has a beta of 0.922, suggesting its less volatile than the S&P 500 by 7.781%.
-
Which is a Better Dividend Stock PTPI or OGEN?
Petros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Oragenics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Petros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Oragenics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTPI or OGEN?
Petros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Oragenics, Inc. quarterly revenues of --. Petros Pharmaceuticals, Inc.'s net income of -$922.7K is higher than Oragenics, Inc.'s net income of -$3.1M. Notably, Petros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Oragenics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Petros Pharmaceuticals, Inc. is 0.22x versus 0.53x for Oragenics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTPIPetros Pharmaceuticals, Inc.0.22x -- -- -$922.7K OGENOragenics, Inc.0.53x -- -- -$3.1M
-
Which has Higher Returns PTPI or PTN?
Palatin Technologies has a net margin of -140.87% compared to Petros Pharmaceuticals, Inc.'s net margin of --. Petros Pharmaceuticals, Inc.'s return on equity of -55.57% beat Palatin Technologies's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital PTPIPetros Pharmaceuticals, Inc.81.79% -$0.03 $3.4M PTNPalatin Technologies-- -- -- -
What do Analysts Say About PTPI or PTN?
Petros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 271639.13%. On the other hand Palatin Technologies has an analysts' consensus of -- which suggests that it could grow by 7338.9%. Given that Petros Pharmaceuticals, Inc. has higher upside potential than Palatin Technologies, analysts believe Petros Pharmaceuticals, Inc. is more attractive than Palatin Technologies.
Company Buy Ratings Hold Ratings Sell Ratings PTPIPetros Pharmaceuticals, Inc.0 0 0 PTNPalatin Technologies0 0 0 -
Is PTPI or PTN More Risky?
Petros Pharmaceuticals, Inc. has a beta of 2.445, which suggesting that the stock is 144.544% more volatile than S&P 500. In comparison Palatin Technologies has a beta of 0.939, suggesting its less volatile than the S&P 500 by 6.103%.
-
Which is a Better Dividend Stock PTPI or PTN?
Petros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Palatin Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Petros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Palatin Technologies pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTPI or PTN?
Petros Pharmaceuticals, Inc. quarterly revenues are --, which are larger than Palatin Technologies quarterly revenues of --. Petros Pharmaceuticals, Inc.'s net income of -$922.7K is higher than Palatin Technologies's net income of --. Notably, Petros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Palatin Technologies's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Petros Pharmaceuticals, Inc. is 0.22x versus -- for Palatin Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTPIPetros Pharmaceuticals, Inc.0.22x -- -- -$922.7K PTNPalatin Technologies-- -- -- --
-
Which has Higher Returns PTPI or TOVX?
Theriva Biologics, Inc. has a net margin of -140.87% compared to Petros Pharmaceuticals, Inc.'s net margin of --. Petros Pharmaceuticals, Inc.'s return on equity of -55.57% beat Theriva Biologics, Inc.'s return on equity of -171.04%.
Company Gross Margin Earnings Per Share Invested Capital PTPIPetros Pharmaceuticals, Inc.81.79% -$0.03 $3.4M TOVXTheriva Biologics, Inc.-- -$0.45 $9.5M -
What do Analysts Say About PTPI or TOVX?
Petros Pharmaceuticals, Inc. has a consensus price target of --, signalling upside risk potential of 271639.13%. On the other hand Theriva Biologics, Inc. has an analysts' consensus of $7.00 which suggests that it could grow by 3528.82%. Given that Petros Pharmaceuticals, Inc. has higher upside potential than Theriva Biologics, Inc., analysts believe Petros Pharmaceuticals, Inc. is more attractive than Theriva Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PTPIPetros Pharmaceuticals, Inc.0 0 0 TOVXTheriva Biologics, Inc.1 1 0 -
Is PTPI or TOVX More Risky?
Petros Pharmaceuticals, Inc. has a beta of 2.445, which suggesting that the stock is 144.544% more volatile than S&P 500. In comparison Theriva Biologics, Inc. has a beta of 0.342, suggesting its less volatile than the S&P 500 by 65.818%.
-
Which is a Better Dividend Stock PTPI or TOVX?
Petros Pharmaceuticals, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Theriva Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Petros Pharmaceuticals, Inc. pays -- of its earnings as a dividend. Theriva Biologics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PTPI or TOVX?
Petros Pharmaceuticals, Inc. quarterly revenues are --, which are smaller than Theriva Biologics, Inc. quarterly revenues of --. Petros Pharmaceuticals, Inc.'s net income of -$922.7K is higher than Theriva Biologics, Inc.'s net income of -$4.4M. Notably, Petros Pharmaceuticals, Inc.'s price-to-earnings ratio is -- while Theriva Biologics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Petros Pharmaceuticals, Inc. is 0.22x versus 0.33x for Theriva Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PTPIPetros Pharmaceuticals, Inc.0.22x -- -- -$922.7K TOVXTheriva Biologics, Inc.0.33x -- -- -$4.4M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 3.95% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is down 0.27% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.18% over the past day.
